British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*

S.G. Keohane1,2 J. Botting3,4 P.G. Budny5,6 O.M. Dolan7 K. Fife8,9 C.A. Harwood10 R. Mallipeddi1,11 J.R. Marsden12 R.J. Motley13 C. Newlands14,15 C. Proby16 A. Rembielak8,17,18 D.N. Slater19 J.A. Smithson20,21 P. Buckley,22 P. Fairbrother,23 M. Hashme,24 M.F. Mohd Mustapa24 L.S. Exton24 and the British Association of Dermatologists’ Clinical Standards Unit

1British Society for Dermatological Surgery, London, UK
2Portsmouth Hospitals University NHS Trust, Portsmouth, PO3 6AD, UK
3Royal College of General Practitioners, London, UK
4Glebe Road Surgery, Barnes, SW13 0DR, UK
5British Association of Plastic Reconstructive and Aesthetic Surgeons, London, UK
6Buckinghamshire Healthcare NHS Trust, Aylesbury, HP21 8AL, UK
7Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, BT12 6BA, UK
8Royal College of Radiologists, Holborn, London, WC2A 3JW, UK
9Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
10Barts Health NHS Trust, Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London, E1 2AT, UK
11St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, SE1 9RT, UK
12Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
13University Hospital of Wales, Health Park, Cardiff, CF14 4XN, UK
14British Association of Oral & Maxillofacial Surgeons, London, UK
15Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK
16University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
17The Christie NHS Foundation Trust, Manchester, M20 4BX, UK
18The University of Manchester, Manchester, M13 9PL, UK
19Royal College of Pathologists, London, E1 8BB, UK
20British Dermatological Nursing Group, Belfast, UK
21East Sussex Healthcare NHS Trust, Eastbourne, BN21 2UD, UK
22Patient representative
23Independent Cancer Patients’ Voice, London, UK
24British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, UK

Correspondence
Steve Keohane.
Emails: stephen.keohane@porthosp.nhs.uk; guidelines@bad.org.uk

Accepted for publication
17 October 2020

Conflicts of interest statements can be found in the Appendix.

This is an updated guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, which includes the Therapy & Guidelines Subcommittee. Members of the Clinical Standards Unit who have contributed are N.J. Levell (Chair, Therapy & Guidelines Subcommittee), B. McDonald, A. Salim, S.L. Chua, G. Petrol, A. Badhan, P. Rakvi, M. Hashme (BAD Information Scientist), L.S. Exton (BAD Guideline Research Fellow) and M.F. Mohd Mustapa (BAD Director of Clinical Standards).

Produced in 2002 by the British Association of Dermatologists (BAD). Reviewed and updated 2009, 2020.

© 2020 British Association of Dermatologists

NICE has renewed accreditation of the process used by the British Association of Dermatologists to produce clinical guidelines. The renewed accreditation is valid until 31 May 2021 and applies to guidance produced using the processes described in the updated guidance for writing a British Association of Dermatologists clinical guideline – the adoption of the GRADE methodology 2016. The original accreditation term began on 12 May 2010. More information on accreditation can be viewed at www.nice.org.uk/accreditation.

*Plain language summary available online
DOI 10.1111/bjd.19621

Linked Comment: Leiter-Stöppke. Br J Dermatol 2021; 184: 384–385.
Purpose and scope

The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of cutaneous squamous cell carcinoma (cSCC). The document aims to:

• offer an appraisal of all relevant literature up to 30 January 2020, focusing on any key developments,
• address important, practical clinical questions relating to the primary guideline objective, and
• provide guideline recommendations and if appropriate research recommendations.

The guideline is presented as a detailed review with highlighted recommendations for practical use in primary, secondary and tertiary care, in the clinic and in the appropriate skin cancer multidisciplinary team (MDT) meetings (see section 3.0). These may be either local skin MDTs (LSMDTs) or specialist skin cancer MDTs (SSMDTs), depending on the clinico-pathological features of the SCC. Clinicians treating people with cSCC should be core members of the appropriate MDT or sanctioned by the MDT to treat the tumour.1 There is also an updated patient information leaflet available on the BAD website (https://www.skinhealthinfo.org.uk/a-z-conditions-treatments/).

Exclusions

The guideline does not cover:

• noncutaneous primary SCC or SCC in situ (Bowen disease); there is a separate guideline for SCC in situ,6
• mucosal SCC; for the lip the remit of this guideline stops at the vermilion border, or
• secondary prevention.3,4

Methodology

This set of guidelines has been developed using the BAD’s recommended methodology;5 further information can be found in Appendix J (see Supporting Information) with reference to the AGREE II instrument (www.agreetrust.org)6 and GRADE (https://www.gradeworkinggroup.org). Recommendations were developed for implementation in the UK National Health Service (NHS).

The guideline development group (GDG) consisted of seven consultant dermatologists (representing England, Northern Ireland, Scotland and Wales), two consultant clinical oncologists (radiation oncologists), a consultant plastic surgeon, a consultant maxillofacial surgeon, a dermatopathologist, a general practitioner, a Macmillan dermatology clinical nurse specialist, two patient representatives and a technical team (consisting of an information scientist, a guideline research fellow and a project manager providing methodological and technical support).

The GDG established several clinical questions pertinent to the scope of the guideline and a set of outcome measures of importance to patients, ranked according to the GRADE methodology7 (see section 2.1; and Appendix A; see Supporting Information).

The GDG agreed to adopt the Royal College of Pathologists dataset for the histological reporting of cSCC.8 Along with Public Health England, this endorses the Union for International Cancer Control 8th edition (UICC8)9 (Tables 1 and 2), rather than the American Joint Committee on Cancer 8th edition cancer staging manual, which covers only head and neck cSCC.10 The GDG agreed that risk is part of a spectrum and not dichotomous, and the evidence from the literature searches supported a division based on low-, high- and very high-risk status. As shown in Figure 1, this division was achieved by integrating clinical, pathological, tumour–nodes–metastasis (TNM) staging and margin criteria.

Table 1 TNM8 (tumour–nodes–metastasis) classification for cutaneous squamous cell carcinoma (cSCC)9

| T categories       |                                                                 |
|--------------------|-----------------------------------------------------------------|
| T1                 | T (tumour) ≤ 2 cm in greatest dimension                         |
| T2                 | T (tumour) > 2 cm to 4 cm in greatest dimension                 |
| T3                 | T (tumour) > 4 cm in greatest dimension or minor bone erosion or specified perineural invasion (≥ 0.1 mm diameter and/or deeper than the dermis and/or a named nerve) or deep invasion (thickness > 6 mm and/or beyond the subcutaneous fat) |
| T4a                | Tumour with gross cortical bone/marrow invasion                 |
| T4b                | Tumour with skull base or axial skeleton invasion including foraminal involvement and/or vertebral foraminal involvement to the epidural space |

| N categories for non-head and neck                               |
|-----------------------------------------------------------------|
| N1 Metastasis in a single node ≤ 3 cm in greatest dimension     |
| N2 Metastasis in a single ipsilateral lymph node, > 3 cm but ≤ 6 cm or in multiple ipsilateral nodes with none > 6 cm in greatest dimension |
| N3 Metastasis in a lymph node > 6 cm in greatest dimension      |

| N categories head and neck region                                |
|-----------------------------------------------------------------|
| N1 Metastasis in a single ipsilateral lymph node ≤ 3 cm in greatest dimension without ENE9 |
| N2a Metastasis in a single ipsilateral lymph node > 3 cm but ≤ 6 cm in greatest dimension without ENE |
| N2b Metastasis in multiple ipsilateral lymph nodes, where none are > 6 cm in greatest dimension without ENE |
| N2c Metastasis in bilateral or contralateral lymph nodes, where none are > 6 cm in greatest dimension without ENE |
| N3a Metastasis in a single or multiple lymph nodes > 6 cm in greatest dimension without ENE |
| N3b Metastasis in a single or multiple lymph nodes with ENE     |

| M categories                                                   |
|-----------------------------------------------------------------|
| M0 No distant metastasis                                       |
| M1 Distant metastasis (including contralateral nodes in non-head and neck cSCC) |

*Extranodal extension (ENE) can be clinical or pathological.
A systematic literature search of the PubMed, MEDLINE, Embase and Cochrane databases was conducted by the technical team to identify key articles on cSCC from 1 January 2007 to 30 January 2020; the search terms and strategies are detailed in Appendix K (see Supporting Information). Additional references relevant to the topic were also isolated from citations in the reviewed literature and the previous versions of the guidelines.11,12 Data extraction, critical appraisal and data synthesis were performed by the technical team, who prepared the evidence summaries, lists of excluded studies and PRISMA diagram. Evidence from included studies was rated according to the GRADE system (high, moderate, low or very low quality).

Recommendations are based on evidence drawn from systematic reviews of the literature pertaining to the clinical questions identified, following discussions with the entire GDG and factoring in all four factors that would affect their strength ratings according to the GRADE approach (i.e. balance between desirable and undesirable effects, quality of evidence, patient values and preferences, and resource allocation). All GDG members contributed towards drafting and/or reviewing the narratives and information in the guideline and supporting information documents. When there was insufficient evidence from the literature, informal consensus was reached based on the experience of the GDG.

The summary of findings with forest plots (Appendix B), clinical evidence summary (Appendix C), tables Linking the Evidence To the Recommendations (LETR) (Appendix D), GRADE evidence profiles indicating the quality of evidence (Appendix E), summary of included studies (Appendix F), narrative findings for noncomparative studies (Appendix G), PRISMA flow diagram (Appendix H) and list of excluded studies (Appendix I) are detailed in the Supporting Information. The strength of recommendation is expressed by the wording and symbols shown in Table 3.

**Clinical questions and outcomes**

The GDG established a number of clinical questions pertinent to the scope of the guideline (for a full review protocol see Appendix A in the Supporting Information). The GDG also established a set of outcome measures of importance to patients for each clinical question, which were ranked according to the GRADE methodology7 by the patient representatives. This uses a nine-point scale, with outcomes ranked 9 being those the patient representatives considered most important. Outcomes ranked 9, 8 or 7 are critical for decision-making; those ranked 6, 5 or 4 are important but not critical for decision-making; and those ranked 3, 2 or 1 are the least important for decision-making. Data on these outcome measures were extracted from the included studies (Appendixes B, C, E, F and G; see Supporting Information).

**Review question 1: treatment**

In people with ‘higher-risk’ primary cSCC, how clinically effective are surgical (standard and Mohs) and nonsurgical treatments (radiotherapy and electrochemotherapy) compared with each other?

- Survivorship 9
- Recurrence rate 9
- Cosmetic outcome 7
- Convenience of treatment 7

**Review question 2: treatment**

In people with low-risk primary cSCC how clinically effective are surgical (standard excision, Mohs, curettage and cautery, cryosurgery and carbon dioxide laser) and nonsurgical treatments (topical therapies, photodynamic therapy or radiotherapy) compared with each other or with no treatment (observation)? (Radiotherapy includes brachytherapy where appropriate.)

- Convenience of treatment 9
- Cosmetic outcome 7
- Recurrence rate 7

**Review question 3: surgical margin**

In people with cSCC who undergo standard surgical excision, what surgical margin and surgical plane should be used?

- Lack of clinical recurrence after 5 years 9
- Lack of clinical recurrence after 2 years 9

**Review question 4: involved margins**

In people with cSCC who undergo excision of the primary tumour and where histological analysis shows either one or more involved or clear-but-close margins (< 1 mm), what is the appropriate subsequent management?

- Survivorship 9
- Recurrence 9

**Review question 5: adjuvant radiotherapy**

In people with primary cSCC following surgical excision with clear histological margins, what is the role of adjuvant radiotherapy in reducing the risk of local recurrence? [‘Adjuvant’ in the guidelines refers to any treatment (radiotherapy) after primary treatment (surgery).]

- Survivorship 9
- Recurrence rate 9
- Cosmetic outcome 7
- Convenience of treatment 6
- Patient-reported outcomes 6

---

**Table 2. TNM8 (tumour–nodes–metastasis) stage groups for cSCC**

| Stage | T       | N       | M       |
|-------|---------|---------|---------|
| I     | T1      | N0      | M0      |
| II    | T2      | N0      | M0      |
| III   | T3      | N0      | M0      |
| IVA   | T1, T2, T3 | N1   | M0      |
| IVB   | Any T   | Any N   | M1      |
| Tumour Factors | Margin status | Patient Factors | Referral to MDT | Follow-up |
|---------------|---------------|----------------|----------------|-----------|
| Tumour diameter ≤20 mm (≤ pT1) | Clear pathology margins in all dimensions (<1 mm) | Immune-competent | LSMDT discussion not needed | Follow-up in secondary care not needed after single post-treatment appointment, where appropriate. |
| Tumour thickness ≤4 mm | | | | Full skin check, examination of regional lymph node basin, discussion of diagnosis and patient education. Patient education about sun protection and skin surveillance is advised. Patients and their GPs should be informed of the risk of further cSCCs. There is a 40% risk of a further keratinocyte cancer within 5 years. If this is suspected, refer via the 2-week wait pathway. |
| Invasion into dermis | | | | |
| No perineural invasion | | Iatrogenic immunosuppression or biological therapies; frailty and/or comorbidities likely to cause some degree of immune compromise; HIV infection stabilised on HAART | | |
| Well differentiated or moderately differentiated histology | | AS FOR HIGH-RISK especially: solid organ transplant recipients; haematological malignancies such as chronic lymphocytic leukaemia or myelofibrosis; other significant immunosuppression | | |
| No lymphovascular invasion | | Very high risk | | |
| (ALL ABOVE FACTORS SHOULD APPLY to denote a low-risk tumour) | | | | |

| Diameter >20 – 40 mm (≤ pT2) | One or more involved or close (<1 mm) pathology margin in a pT1 tumour. Close pathology margins (<1 mm) in a pT2 tumour. | Iatrogenic immunosuppression or biological therapies; frailty and/or comorbidities likely to cause some degree of immune compromise; HIV infection stabilised on HAART | | |
| Thickness >4 mm – 6 mm | | | | |
| Invasion into subcutaneous fat | | | | |
| Perineural invasion present – dermal only; nerve diameter <0.1 mm | | | | |
| Poorly differentiated histology | | | | |
| Lymphovascular invasion | | | | |
| Tumour site ear or lip | | | | |
| Tumour arising within scar or area of chronic inflammation | | | | |
| (ANY SINGLE FACTOR denotes a high-risk tumour) | | | | |

**Figure 1** Guidance for referral to LSMDTs and SSMDTs. This referral guidance relates to primary cSCC, where treatment has been excisional surgery with curative intent. Factors associated with risk of poor disease-related outcomes (local recurrence, nodal metastasis, disease-specific death) in multiple studies using univariate or multivariate analysis.13–18 cSCC, cutaneous squamous cell carcinoma; GP, general practitioner; HAART, highly active antiretroviral therapy; LSMDT, local skin cancer multidisciplinary team; SCID, severe combined immunodeficiency; SSMDT, specialist skin cancer multidisciplinary team. *Review of nodal basins in the head and neck should be per the criteria of the head and neck MDT. [Colour figure can be viewed at wileyonlinelibrary.com]
**Review question 6: metastatic squamous cell carcinoma**

In people with any metastasis from cSCC how clinically effective are standard surgical and nonsurgical treatments (chemotherapeutic therapy, radiotherapy, immunotherapy) compared with each other or with no treatment (observation)? (Radiotherapy includes brachytherapy where appropriate.)

- Survivorship 9
- Recurrence rate 9
- Cosmetic outcome 7
- Convenience of treatment 7
- Patient-reported outcomes 6

**Review question 7: follow-up**

In people with a diagnosed higher-risk cSCC what is the appropriate follow-up period following treatment?

- Survivorship 9
- Recurrence 9
- Metastases 9
- Patient-reported outcomes 6

Note: in Mohs surgery the tumour is curetted or surgically debulked, and the defect usually excised with a small (1–2 mm) margin of surrounding skin. The patient waits with a dressed wound pending histological confirmation by the Mohs surgeon that the tumour has been completely removed. If residual tumour is identified, a further layer of tissue is removed, and the process repeated until the surgical wound is confirmed to be tumour free. The wound is then repaired by conventional surgical techniques.

**Summary of recommendations**

There are few randomized controlled trials (RCTs) to support the following guidelines for the management of cSCC. The following recommendations and ratings were agreed upon unanimously by the core members of the GDG and patient representatives. The recommendations cover suspected and diagnosed cSCC. All recommendations would also generally relate to children, young people and adults, unless specified otherwise. Those under 24 years of age with cSCC should be managed by the SSMDT but must additionally be referred to the appropriate children’s, teenagers’ or young adults’ service for their specific expertise. These guidelines do not include specific recommendations for subungual or periungual SCCs.

For further information on the wording used for recommendations and strength of recommendation ratings see Table 3. The evidence for recommendations is based on the studies as listed (for details and discussion of the evidence see Appendixes B–F in the Supporting Information). The GDG recommendations relating to referral pathways are based on discussion and clinical experience, as evidence-based details are not available at the time of writing. The GDG is aware of the lack of high-quality evidence for some of these recommendations, and therefore strong recommendations with an asterisk (*) are based on available evidence, as well as consensus and specialist experience. Good practice point (GPP) recommendations are derived from informal consensus.

**Pretreatment**

**R1 (↑↑)** Obtain histological confirmation of cSCC lesions in the event of diagnostic uncertainty, before planning definitive treatment. This must be a representative sample of the tumour; in most instances, this will be a full-thickness incisional biopsy ideally incorporating both the peripheral and the deep margins.

**R2 (GPP)** Offer discussion on the risks and benefits of all treatment options (outcomes, function, cosmesis) to people with cSCC and their families or carers and make the treatment decision together.

**R3 (↑↑)** Record the maximum clinical cSCC lesion dimension prior to any diagnostic or treatment procedure (usually diameter, in millimetres), the plane of the deep-excision margin, whether it is a recurrent tumour or in field of previous

---

**Table 3 Strength of recommendation ratings**

| Strength | Wording | Symbol | Definition |
|----------|---------|--------|------------|
| Strong recommendation for the use of an intervention | ‘Offer’ (or similar, e.g. ‘use’, ‘provide’, ‘take’, ‘investigate’ etc.) | ↑↑ | Benefits of the intervention outweigh the risks; most patients would choose the intervention while only a small proportion would not; for clinicians, most of their patients would receive the intervention; for policymakers, it would be a useful performance indicator |
| Weak recommendation for the use of an intervention | ‘Consider’ | ↑ | Risks and benefits of the intervention are finely balanced; most patients would choose the intervention but many would not; clinicians would need to consider the pros and cons for the patient in the context of the evidence; for policymakers it would be a poor performance indicator where variability in practice is expected |
| No recommendation | 'Do not offer’ | Θ | Insufficient evidence to support any recommendation |
| Strong recommendation against the use of an intervention | 'Do not offer’ | ↓↓ | Risks of the intervention outweigh the benefits; most patients would not choose the intervention while only a small proportion would; for clinicians, most of their patients would not receive the intervention |

© 2020 British Association of Dermatologists

British Journal of Dermatology (2021) 184, pp401–414
radiotherapy, and the immune status of the patient, on the specimen request form for the pathologist.

R4 (GPP) Take a good-quality clinical photograph of the cSCC lesion for the patient record to aid future management and assessment of the area after healing. In multisite disease the lesions to be treated should ideally be marked on the photograph to limit the risk of wrong-site procedures.

Treatment options for primary cutaneous squamous cell carcinoma

Standard surgical excision

R5 (↑↑) Offer* standard surgical excision as the first-line treatment option to people with resectable primary cSCC.

R6 (↑↑) Peri-is peripheral tumour margins should be determined under bright lighting and magnification or dermoscopy. Excise* with a clinical peripheral surgical margin of

- ≥ 4 mm for a low-risk cSCC tumour,
- ≥ 6 mm for a high-risk cSCC tumour,
- ≥ 10 mm for a very high-risk cSCC tumour.

For definition of the levels of risk see Figure 1.13–18

R7 (↑↑) Ensure at least a 1-mm histological clearance of cSCC excisions at all margins by including sufficient peripheral and deep tissues (see R6 for appropriate standard surgical excision margins).

- For mobile lesions the deep margin should be within the next clear surgical plane, and on the scalp the excision should include the galea.
- For deeply infiltrating or fixed lesions at any site, achieving an uninolved deep histological margin may require inclusion of one or more of the following – fascia, muscle, bone or other underlying structure – which may be determined clinically or by imaging, or both.
- Consideration should be given to excision of a further, orientated, deep-margin specimen where possible, if there is clinical concern at the time of resection that the resection is close or incomplete.
- Whenever possible confirm uninolved histological margins by paraffin section analysis prior to reconstruction involving complex tissue rearrangement where dressings or temporizing cover can reasonably be achieved. However, in the context of extensive ablative resections (e.g. scalp into the calvarium or abutting dura, ear–parotid–temporal bone, composite maxillofacial resections etc.) this approach is unlikely to be feasible due to immediate reconstructive requirements.
- Where there is extensive disease, and/or involvement of specific anatomical areas, consider liaising with one or more additional MDT depending on the site of the cSCC.

R8 (↑↑) Manage and report excised cSCC specimens according to the Royal College of Pathologists dataset.6

Multidisciplinary team discussion

R9 (GPP) Document the risk status of cSCC tumour as low risk, high risk or very high risk in the patient notes (Figure 1).

R10 (↑↑) T1 cSCC tumours excised with histologically clear margins of at least 1 mm, in the absence of other high-risk factors, do not need routine discussion at an MDT (Figure 1).

R11 (↑↑) Review the histology of people with cSCC with one or more involved or clear-but-close margins (< 1 mm) at an appropriate skin MDT (Figure 1).

R12 (↑) Consider the risk factors for the patient and the margin, site and tumour stage in people with cSCC with one or more clear-but-close margins (< 1 mm). Consider observation in immunocompetent people with cSCC with a low-risk tumour (Figure 1).

R13 (↑↑) Offer further wide local excision (with likely delayed reconstruction), Mohs micrographic surgery, or adjuvant radiotherapy to people with cSCC with one or more involved margins, or close margins (< 1 mm), where patient or tumour factors confer higher risk.

R14 (GPP) Offer active treatment to immunosuppressed people with cSCC with one or more clear-but-close (< 1 mm) or involved margins with structured follow-up and surveillance.

R15 (↑↑) Discuss at an SSMDT people with cSCC with symptomatic perineural invasion and/or radiological evidence of perineural invasion. If discussed at a skin MDT, skull base or head and neck MDT opinion may be required. Aggressive surgical excision of the involved nerve should be the first step, where technically possible, followed by consideration of adjuvant radiotherapy.

Mohs micrographic surgery

R16 (↑) Consider Mohs micrographic surgery in selected people with cSCC following SSMDT discussion, particularly where tumour margins are difficult to delineate or in sites where tissue conservation is important for function.

Radiotherapy: primary and postoperative (adjuvant radiotherapy)

R17 (↑↑) Discuss people with histologically proven cSCC being considered for radiotherapy at an MDT (LSMDT or SSMDT) with a clinical oncologist present.

R18 (↑↑) Offer primary radiotherapy

- to selected people with cSCC as a treatment option following appropriate discussion at the appropriate skin MDT and/or with a clinical or radiation oncologist, factoring in patient preference, and
- to people with cSCC when surgery is not feasible or would be challenging or likely to result in an unacceptable functional or aesthetic outcome.
R19 (†) Consider adjuvant radiotherapy in people with cSCC
• if pathological excision margins are clear but close (< 1 mm) following discussion at an appropriate skin MDT, where a clinical oncologist is present, and
• with completely excised T3 tumours, where there are multiple high-risk factors, including those > 6 mm in thickness (depth) and invasion beyond subcutaneous fat.

R20 (††) Offer adjuvant radiotherapy to people with incompletely excised cSCC, where further surgery is not possible (or is not chosen by the patient) and in those at high risk of local recurrence
• in the case of perineural invasion (multifocal, named nerve and/or diameter of nerve > 0.1 mm, below the dermis),
• in recurrent disease, and
• in those who are immunocompromised (see R21).

R21 (††) Do not offer postoperative radiotherapy to people with completely excised T1 or T2 cSCC and with microscopic, dermal-only, nerve diameter < 0.1 mm perineural invasion.

R22 (†) Consider conformal radiotherapy including the entire course of the involved nerve in people with cSCC with symptomatic perineural invasion and/or radiological evidence of perineural invasion when surgery is inappropriate, after carefully weighing the benefits and side-effects from radiotherapy to such an extensive radiotherapy treatment field.

R23 (GPP) Inform younger people with cSCC (age < 60 years), especially if they are an organ transplant recipient, of the very low risk of radiation-induced, in-field malignancy in the future. Take this risk into account when making any treatment decision.

Curettage and cautery

R24 (†) Consider curettage and cautery with curative intent in immunocompetent people with small (< 1 cm), well-defined, nonrecurrent, clinically low-risk cSCC.

R25 (GPP) Review the histology of cSCC removed by curettage and cautery to identify high-risk or very high-risk features. If these are identified, the case should be discussed at an appropriate MDT regarding further management.

Locally advanced, recurrent and metastatic cutaneous squamous cell carcinoma

R26 (GPP) Do not routinely offer imaging of the draining nodal basin to people with cSCC in the absence of suspected or clinically detectable regional nodal involvement. Very high-risk lesions, such as pT2 or greater lip cSCC, carry a high risk of occult metastasis and consideration can be given to high-resolution ultrasound scan of the regional nodes in the clinically N0 setting.

R27 (††) Initiate an individualized SSMDT, multimodality and imaging treatment plan for people
• with regional lymph node metastasis,
• who are immunocompromised and with locally advanced and/or metastatic cSCC,
• with in transit metastases from cSCC, and
• with metastatic cSCC who have had further locoregional relapse following lymphadenectomy.

R28 (GPP) Where assessment of the anatomical extent of a primary cSCC warrants imaging, consider including regional lymph nodes in the scan.

R29 (GPP) Only consider sentinel lymph node biopsy for specific, high-risk cases of primary cSCC in the context of a clinical trial or SSMDT discussion.

R30 (GPP) Offer ultrasound-guided fine-needle aspiration cytology to people with cSCC with clinically suspicious nodes. If they are negative and suspicion remains, this can be repeated, although core or open-biopsy histology may be required.

R31 (GPP) Undertake high-resolution magnetic resonance imaging (MRI) of the involved area in people with cSCC with in transit metastasis or regional perineural invasion of named nerves. Discuss with a radiologist if MRI is contraindicated. (In transit metastasis is a type of metastasis in which skin cancer spreads through a lymph vessel and begins to grow between the area of previous treatment and the nodal basin.)

R32 (††) Offer therapeutic regional lymphadenectomy to people with head and neck cSCC with regional lymph node metastasis. (Regional lymphadenectomy is a surgical procedure in which the lymph nodes that drain the site of the tumour are removed to an extent that has therapeutic rather than diagnostic or palliative intent. The tissue is subsequently checked under the microscope for signs of cancer.) Imaging is required preoperatively to define the extent of locoregional relapse, and to identify distant metastatic disease (also see R36). The head and neck imaging should include locoregional MRI or computed tomography (CT), and CT imaging of the chest as a minimum. The surgery should be performed by a designated surgeon who is a core member of the SSMDT pathway and compliant with prevailing multispecialty guidance.

• Where the parotid gland has proven nodal metastasis and the neck is cN0, a therapeutic parotidectomy, usually the superficial lobe alone, should be combined with an elective selective neck dissection of levels I–III. If an anterior scalp or temple primary site has proven neck nodal metastasis, consideration should be given to an elective superficial parotidectomy at the time of therapeutic neck nodal dissection.

• Where the neck has proven nodal metastasis, the therapeutic neck dissection should include levels and structures to maximize tumour clearance, while minimizing unnecessary morbidity. It may be appropriate to preserve a clinically and radiologically uninvolved level I where the primary tumour was posterior, thus to carry out a posterolateral neck dissection of levels II–V. Consideration can also be given to preservation of an uninvolved, level V where the primary tumour site was in the central lower face.
• Nodes in the superficial system, such as the occipital nodes, or external jugular node should also be included in a dissection, according to the primary site, and the identified sites of metastasis.

R33 (††) Offer therapeutic regional lymphadenectomy to people with non-head and neck cSCC with regional lymph node metastases in axillary, inguinoscrotal or other peripheral draining nodes. Imaging is required preoperatively to define the extent of locoregional relapse, and to identify distant metastatic disease (also see R36). In the axilla, CT imaging should include the neck, chest and axilla as a minimum and the surgery should include levels I–III. In the inguinoscrotal region CT imaging should include the chest–abdomen–pelvis and to mid-thigh level and the surgery should include superficial and deep levels.

• Therapeutic extended ilio-inguinoscrotal lymphadenectomy is indicated in those with additional iliac nodal cSCC on imaging or cytology.

• Elective extended ilio-inguinoscrotal lymphadenectomy should also be considered, at the SSMDT, for people with extensive inguinoscrotal relapse (multiple nodes, any > 3 cm, plus or minus extranodal extension) who do not have concurrent evidence of iliac relapse on imaging or cytology but are deemed to be at high risk of microscopic disease in the extended basin.

• Nodal disease at other ectopic sites should have individualized imaging under guidance from the SSMDT.

• The surgery should be performed by a designated surgeon of the SSMDT pathway who is compliant with prevailing multispeciality guidance.

R34 (††) Offer adjuvant radiotherapy following therapeutic regional lymphadenectomy to people with cSCC with high-risk pathology (e.g. two or more nodes, large nodes and extracapsular extension), defined by UICC8 as ≥ pN1.

R35 (GPP) Consider surgical resection (with or without adjuvant radiotherapy) or primary radiotherapy in people with locally recurrent cSCC.

R36 (GPP) Consider regional lymphadenectomy or regional lymph node basin irradiation in selected people with cSCC for disease control even in the presence of distant metastases, especially in those undergoing multimodality treatment.

R37 (†) Consider immune checkpoint inhibitor treatment in people with locally advanced cSCC where curative surgery or radiotherapy is not reasonable, or those with metastatic cSCC, except patients with organ transplants or those who have significant autoimmune conditions.

R38 (†) Consider systemic chemotherapy or epidermal growth factor receptor (EGFR) inhibitors in people with metastatic cSCC with contraindications to immune checkpoint inhibitors. Responses are generally short lived and chemotherapy is poorly tolerated in elderly and frail people, and consideration for best supportive care should be made. EGFR inhibitors are unlicensed for cSCC in the UK.

R39 (GPP) Consider electrochemotherapy in people with locally advanced cSCC in palliative settings if other local or systemic therapies are not appropriate.

Follow-up

R40 (††) Offer access to a key worker to people with cSCC, ideally a clinical nurse specialist, as part of an ongoing treatment prevention package. Provide information on the diagnosis and management of cSCC.

R41 (GPP) Follow up people with cSCC by examining the skin and lymph node basins and with any other appropriate clinical examination.

R42 (GPP) Educate people with cSCC on self-examination (skin and lymph nodes) and sun protection by providing appropriate verbal and written information (e.g. www.bad.org.uk/leaflets).

R43 (GPP) Offer people with low-risk cSCC a single post-treatment appointment, where appropriate, to check histopathology results, conduct skin and nodal surveillance and facilitate patient education on self-examination and surveillance of patients’ own digital photographs (patient education could have already taken place at the pretreatment appointment). Provide information on the 5-year risk of developing further cSCC and on how to access a referral, including the 2-week-wait pathway back into the system if they suspect a new lesion.

R44 (GPP) Offer people with high-risk cSCC (especially when several risk factors apply) post-treatment follow-up appointments at 4-monthly intervals for 12 months, then at 6-monthly intervals for a further 12 months. The initial follow-up should be with secondary-care clinicians to facilitate skin surveillance and patient education on self-examination. Later appointments may be with other clinicians able to recognize recurrences and new skin cancers according to local arrangements approved by the appropriate skin MDT.

R45 (GPP) Offer people with very high-risk cSCC post-treatment follow-up appointments at 4-monthly intervals for 24 months, then at 6-monthly intervals for a further 12 months. The initial follow-up should be with secondary-care clinicians to facilitate skin surveillance and patient education on self-examination. Later appointments may be made with other clinicians able to recognize recurrences and new skin cancers according to local arrangements approved by the appropriate skin MDT. People who have a high risk of developing further high-risk, primary cSCC, such as organ transplant recipients, should remain under lifelong skin surveillance.

R46 (GPP) Offer people with metastatic cSCC post-treatment follow-up appointments at 3-monthly intervals for 24 months, then at 6-monthly intervals for a further 36 months, with potential longer-term review dependent on patient factors.
Imaging should be performed on the basis of clinical findings, with SSMDT discussion if appropriate.

**Insufficient evidence to support any recommendation**

- There is insufficient evidence to support any recommendation for cryotherapy, CO₂ laser or topical therapies in the treatment of cSCC.

**List of key future research recommendations**

The following list outlines future research recommendations (FRRs).

- **FRR1** Research should identify which clinicopathological or molecular factors predict poor outcome, which might facilitate a scoring system (1–5) for risk.
- **FRR2** Future cancer-related RCTs need to include more people with cSCC, with stratification of the results by risk factors.
- **FRR3** Future skin cancer clinical studies need to differentiate outcomes clearly by histopathology (i.e. SCC or basal cell carcinoma) and stage.
- **FRR4** Prospective, head-to-head RCTs for primary cSCC reporting (i) 5-year recurrence rates, (ii) quality of life and (iii) long- and short-term adverse effects, including pain, function and cosmetic appearance
  - comparing surgical interventions with modern standardized two-dimensional histopathology,
  - evaluating the role of adjuvant radiotherapy in resected primary cSCC,
  - comparing further surgery vs. radiotherapy in incompletely resected primary cSCC, and
  - comparing adjuvant radiotherapy (margins, techniques) after surgical excision of higher-risk cSCC.
- **FRR5** All future RCTs involving cSCC need to report standardized outcome measures (e.g. time to recurrence, standardized quality-of-life scales) to facilitate comparisons and pooling of data across studies.
- **FRR6** A study evaluating the cost and resource implications of different treatment options for people with cSCC in the UK NHS healthcare setting.
- **FRR7** Alternative immunotherapy strategies suitable for people with inoperable, locally advanced cSCC, not amenable to radical radiotherapy, or metastatic cSCC in whom immune checkpoint inhibitors are contraindicated.
- **FRR8** There is a need for a review of the treatments of cSCC in those who are at increased risk of developing SCC (e.g. those with impaired immunity or genetic conditions).
- **FRR9** The role of sentinel lymph node biopsy in the staging of very high-risk cSCC given the propensity of these tumours to metastasize.

**Algorithms**

The recommendations, discussions in the LETRs (Appendix D; see Supplementary Information) and consensus specialist experience were used to inform the algorithm and pathway of care (Figures 2 and 3).

**Background**

**Definition**

Primary cutaneous squamous cell carcinoma (cSCC) is a malignant tumour that arises from the keratinocytes of the epidermis or its hair follicles. It is locally invasive and has the potential to metastasize.

**Incidence and aetiology**

The rate of nonmelanoma skin cancer is at least 2–4 times higher than that of the next most common tumour in the UK, which is breast cancer. Recent evidence suggests that this is still an underestimate for skin cancer due to under-reporting. cSCC is the sixth most common cancer in the UK and its incidence continues to rise, not only in the UK but also in many other countries. This will have an increasing impact on planning for NHS services and on histopathology services.

Its occurrence is usually related to chronic ultraviolet (UV) exposure and is therefore especially common in people with sun-damaged skin, fair skin, albinism and xeroderma pigmentosum. Additionally, increasing longevity may also be responsible for the increasing incidence of these tumours. It may develop de novo – as a result of previous exposure to UV and ionizing radiation, or chemicals such as pesticides, herbicides or arsenic; within chronic wounds, scars, burns, ulcers or sinus tracts; or from pre-existing lesions such as SCC in situ (Bowen disease). A high incidence of aggressive cSCC is found in individuals with recessive dystrophic epidermolysis bullosa (RDEB), where it is a major cause of death. In RDEB, the aetiology of cSCC is chronic wounding, not UV exposure. Individuals with impaired immune function, for example those receiving immunosuppressive drugs following allogeneic organ transplantation or for inflammatory disease, and those with lymphoma or leukaemia, are at increased risk of this tumour. Some cSCCs are associated with human papillomavirus infection. The risk of cSCC with the ‘biologic’ therapies (for inflammatory or haematological disease) has yet to be accurately quantified.

There is good evidence linking cSCCs with chronic actinic damage (including that from the use of tanning devices) and to support sun avoidance, use of protective clothing and effective sun blocks in the prevention of actinic keratoses and cSCCs. These measures are particularly important for people receiving long-term immunosuppressive medication. People who have had psoralen–UVA therapy for skin conditions may also be at higher risk. cSCC may also occur in patients who are being treated with BRAF inhibitors for melanoma.

People with organ transplants are at high risk of developing cSCC. Skin surveillance to allow early detection and treatment, and measures to prevent cSCC, should be part of their routine care. In patients with multiple, frequent or high-risk cSCCs
Figure 2 Staging and management pathway of primary cutaneous squamous cell carcinoma (cSCC). FNAB, fine-needle aspiration biopsy; FNAC, fine-needle aspiration cytology; LSMDT, local skin cancer multidisciplinary team; SSMDT, specialist skin cancer multidisciplinary team; USS, ultrasound scan. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 3  Treatment pathway for primary cutaneous squamous cell carcinoma (cSCC) in adults. ART, adjuvant radiotherapy; LaSCC, locally advanced squamous cell carcinoma; mSCC, metastatic squamous cell carcinoma; SSMDT, specialist skin cancer multidisciplinary team. [Colour figure can be viewed at wileyonlinelibrary.com]

© 2020 British Association of Dermatologists
British Journal of Dermatology (2021) 184, pp401–414
consideration should be given to modifying immunosuppressive regimens\textsuperscript{34,35} and the prophylactic use of systemic retinoids,\textsuperscript{36–38} which may also be valuable in other high-risk groups.\textsuperscript{39} Nicotinamide should also be considered in this situation.\textsuperscript{40} Therapies such as topical 5-fluorouracil\textsuperscript{41} and imiquimod,\textsuperscript{42} and photodynamic therapy\textsuperscript{43} may have useful roles in preventing skin dysplasia and therefore decreasing the risk of skin cancers in high-risk renal transplant recipients, but substantive evidence is awaited.

**Diagnosis and investigation**

**Clinical presentation**

SCC usually presents as an indurated nodular keratinizing or crusted tumour that may ulcerate, or it may present as an ulcer without evidence of keratinization. All patients in whom there is a possibility of a cSCC should be referred urgently to an appropriately trained specialist who is attached to an LSMDT, usually in their local dermatology department’s rapid-access skin cancer clinic.\textsuperscript{44}

**Diagnosis and staging**

The handling of skin cancer specimens and their histopathological diagnosis and reporting should conform to the Royal College of Pathologists dataset for primary cSCC.\textsuperscript{8} The Royal College of Pathologists and Public Health England have adopted UICC\textsuperscript{8} TNM\textsuperscript{9} for the staging of melanoma and non-melanoma skin cancer.

**Recommended audit points**

In the last 20 consecutive patients with cSCC is there clear documentation for or evidence of the
1. Name and grade of the surgeon who carried out the surgery?
2. Patient being instructed in self-examination and provided with written patient information (e.g. www.bad.org.uk/leaflets)?
3. Site and maximum dimension (usually diameter) of the lesion?
4. Lesion being fixed or mobile beneath the skin (head, neck, trunk and limbs)?
5. Lesion having tarsal plate or lid margin involvement, or not (eyelid)?
6. Immunosuppressive status of the patient?
7. Risk status of the lesion (low risk, high risk or very high risk)?
8. Lesion having associated clinically detectable nodes, or being clinically N0?
9. Standard surgical excision, detailing
   a. The surgical margins of excision (R6; and see below)?
      Note: these are \( \geq 4 \) mm for low-risk, \( \geq 6 \) mm for high-risk and \( \geq 10 \) mm for very high-risk cSCC.

10. Histological margins in all planes following standard surgical excision? Note: these are defined as clear (\( \geq 1 \) mm), clear but close (\(< 1 \) mm) or involved (0 mm).
11. Appropriate follow-up protocols (R43, R45, R46 and see below) by different members of the MDT, including clinical nurse specialists? Note: follow-up schedules are low-risk: one appointment for diagnosis and education; high-risk: a follow-up every 4 months in the first year then every 6 months in the second year; and very high-risk: a follow-up every 4 months in the first and second years, then every 6 months in the third year.
12. Recording and review of histologically proven recurrence of cSCC during follow-up periods following both surgical and nonsurgical treatments?

The audit recommendation of 20 cases per department is to reduce variation in the results due to a single patient and allow benchmarking between different units (Appendix I; see Supporting Information).

**Stakeholder involvement and peer review**

The draft document and Supporting Information were made available to the BAD membership, the Royal College of General Practitioners (RCGP), the Royal College of Pathologists (RCPath), the Royal College of Radiologists (RCR), the British Association of Oral and Maxillofacial Surgeons (BAOMS), the British Association of Head and Neck Oncologists (BAHNO), the British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS), the British Society for Dermatological Surgery (BSDS), the British Dermatological Nursing Group (BDNG), the British Association of Skin Cancer Nurse Specialists (BASCNS) and the Primary Care Dermatological Society (PCDS). The comments received were actively considered by the GDG. Following further review, the finalized version was sent for peer review by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines Subcommittee) prior to submission for publication.

**Limitations of the guideline**

This document has been prepared on behalf of the BAD and is based on the best data available when the document was prepared. It is recognized that under certain conditions it may be necessary to deviate from the guidelines and that the results of future studies may require some of the recommendations herein to be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence. Limiting the review to English and German-language references was a pragmatic decision but the authors recognize this may exclude some important information published in other languages.
Plans for guideline revision

The proposed revision date for this set of recommendations is scheduled for 2025; where necessary, important interim changes will be updated on the BAD website.

Acknowledgments

We are very grateful to Professor Fiona Bath-Hextall for her advice on formulating the protocols, and Dr Stephen Kownacki (PCDS), Dr Virginia Wolstenholme (RCR), Ms Liz Freeman (BDNG) and Dr Robert Herd for their contribution at the inception of these guidelines. We thank the patient representatives Ms Patricia Fairbrother and Mr Paul Buckley for their input in formulating the clinical questions, ranking of the outcomes, reviewing the evidence and formulating the recommendations, as well as all of those who commented on the draft during the consultation period.

References

1 National Institute for Health and Care Excellence. Improving outcomes for people with skin tumours including melanoma. Available at: https://www.nice.org.uk/guidance/csg8/evidence/full-guideline-2006-pdf-2191950665 (last accessed 20 October 2020).
2 Morton CA, Birnie AJ, Edey DJ. British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014. Br J Dermatol 2014; 170:245–60.
3 National Comprehensive Cancer Network. NCCN Guidelines: squamous cell skin cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf (last accessed 20 October 2020).
4 Lopez AT, Carvajal RD, Geskin L. Secondary prevention strategies for nonmelanoma skin cancer. Oncology (Williston Park) 2018; 32:195–200.
5 Mohd Mustapa MF, Exton LS, Bell HK et al. Updated guidance for writing a British Association of Dermatologists clinical guideline: the adoption of the GRADE methodology 2016. Br J Dermatol 2017; 176:44–51.
6 Browsers M, Kho ME, Brownow GP et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010; 182:839–42.
7 Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924–6.
8 Slater DN, Barrett P. Dataset for the histological reporting of primary cutaneous squamous cell carcinoma and regional lymph nodes. Available at: https://www.rcpath.org/upload/assets/9c1d8f71-5d3b-4508-8e620f0f1e1f4a39/Dataset-for-histopathological-reporting-of-primary-invasive-cutaneous-squamous-cell-carcinoma-and-regional-lymph-nodes.pdf (last accessed 20 October 2020).
9 Brierley JD, Gospodarowicz MK, Wittekind C. Skin tumours. In: Brierley JD, Gospodarowicz MK, Wittekind C, eds), Chichester: John Wiley and Sons, 2017; 171–81.
10 Califano JA, Lydiatt WM, Nehal KS et al. Cutaneous squamous cell carcinoma of the head and neck. In: AJCC Cancer Staging Manual, 8th edn (Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK et al., eds). New York: Springer; 2017: 171–81.
11 Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol 2002; 146:18–25.
12 Motley RJ, Preston PW, Lawrence CM. Multi-professional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Available at: http://www.bad.org.uk/shared/get-file.ashx?id=59&itemtype=document (last accessed 20 October 2020).
13 Eigentler TK, Leiter U, Häfner HM et al. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Invest Dermatol 2017; 137:2309–15.
14 Rose AM, Nicoll KJ, Moinie A et al. Patients with low-risk cutaneous squamous cell carcinoma do not require extended out-patient follow-up. J Plast Reconstr Aesthet Surg 2017; 70:852–5.
15 Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976–90.
16 Ruiz ES, Karia PS, Besaw R et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition versus the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol 2019; 155:819–25.
17 Jambusaria-Pahlajani A, Kanetsky PA, Karia PS et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013; 149:402–10.
18 Wehner MR, Lemos E, Parvataneni R et al. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol 2015; 151:382–8.
19 National Institute for Health and Care Excellence. Skin cancer. Quality standard Q5130. Available at: https://www.nice.org.uk/guidance/qs130 (last accessed 20 October 2020).
20 Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26:1–26.
21 Cancer Research UK. Non-melanoma skin cancer incidence. Available at: https://www.cancerresearchuk.org/health-professional/cancerstatistics/statistics-by-cancer-type/non-melanoma-skin-cancer#heading-zero (last accessed 20 October 2020).
22 Venables ZC, Nijsten T, Wong KM et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the UK 2013–15: a cohort study. Br J Dermatol 2019; 181:474–82.
23 Que SKT, Zwald FO, Schmuits CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018; 78:337–47.
24 Green AC, Olsen CM. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol 2017; 177:373–81.
25 Goon PK, Greenberg DC, Igal L et al. Squamous cell carcinoma of the skin has more than doubled over the last decade in the UK. Acta Derm Venereol 2016; 96:820–1.
26 Tommasino M. HPV and skin carcinogenesis. Papillomavirus Res 2019; 7:129–31.
27 Scott FI, Mamtani R, Brensinger CM et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 2016; 152:164–72.
28 Patel RV, Clark LN, Lebwohl M et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60:1001–17.
29 Karagas MR, Stannard VA, Mott LA et al. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst 2002; 94:224–6.
30 van der Pols JC, Williams GM, Pandeya N et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2546–8.
31 Ulrich C, Jürgensen JS, Degen A et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a
sunscreen: a 24 months, prospective, case–control study. Br J Dermatol 2009; 161 (Suppl. 3):78–84.
32 Stern RS, PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralan and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66:553–62.
33 Gibney GT, Messina JL, Fedorenko IV et al. Paradoxical oncogenesis – the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013; 10:390–9.
34 Mittal A, Colegio OR. Skin cancers in organ transplant recipients. Am J Transplant 2017; 17:2509–30.
35 Collins L, Quinn A, Stasko T. Skin cancer and immunosuppression. Dermatol Clin 2019; 37:83–94
36 Otley CC, Stasko T, Tope WD et al. Chemoprevention of non-melanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Sunq 2006; 32:562–8.
37 Herold M, Good AJ, Nielson CB et al. Use of topical and systemic retinoids in solid organ transplant recipients: update and review of the current literature. Dermatol Sunq 2019; 45:1442–9.
38 Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol 2018; 78:249–61.
39 Nysten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49:644–50.
40 Chen AC, Martin AJ, Choy B et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373:1618–26.
41 Weinstock MA, Thwin SS, Siegel JA et al. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. JAMA Dermatol 2018; 154:167–74.
42 Brown VL, Atkins CI, Ghali L et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141:985–93.
43 Togsveld-Bo K, Omland SH, Wulf HC et al. Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial. Am J Transplant 2015; 15:2986–90.
44 National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE clinical guideline NG12. Available at: https://www.nice.org.uk/guidance/ng12 (last accessed 20 October 2020).

Appendix

Conflicts of interest

The following interests were declared over the duration of the guideline development. P.G.B.: RCSEng RSPA Plastics South Central (demitted 2016), Deputy Chair TVCN Skin Cancer TSSG (demitted 2020) (specific). K.F.: (i) advisory boards – ESAI, IPSEN, Roche, Novartis, Merck, Pfizer and Busa (specific); (ii) speaker fees and consultancy – BMS, Pfizer, MSD (non-specific); (iii) conference hospitality – Novartis, Ipsen (specific); (iv) institutional research funding – Roche, MSD, Eloxelis (specific). C.A.H.: (i) speaker and honoraria for Sanofi (specific); (ii) member of the NCRI Skin Group (specific) and member of the EADO guidelines development group for cSCC (specific). J.R.M.: member of the NCRI non-melanoma skin cancer subgroup (specific). C.N.: (i) member of the NCRI non-melanoma skin cancer subgroup (specific); (ii) has shares in a private general practitioner web-based company (non-specific). C.P.: (i) Chair of the Scottish Dermatological Society Skin Cancer Group (specific); (ii) member of the NCRI Skin Group (specific); (iii) member of the NCRI non-melanoma skin cancer subgroup (specific); (iv) clinical expert for appraisal of cemiplimab for cSCC for NICE (April 2019) (specific). A.R.: (i) member of the NCRI Skin Group (specific); (ii) member of the NCRI non-melanoma skin cancer subgroup (specific); (iii) Non-Melanoma Skin Cancer Advisory Board prior to ESMO 2018 on cemiplimab for Sanofi (specific). D.N.S.: Royal College of Pathologists Lead on Skin Cancer Datasets (specific). S.G.K., J.B., O.M.D., R.M., R.J.M., C.N., J.A.S., P.B., P.F., M.H., M.F.M.M. and L.S.E. declare they have no conflicts of interest.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Appendix A Review protocol.
Appendix B Forest plots.
Appendix C Clinical evidence summary.
Appendix D Linking Evidence To Recommendations (LETR).
Appendix E GRADE evidence tables.
Appendix F Summary of included studies.
Appendix G Narrative findings for non-comparative studies.
Appendix H PRISMA diagram: study selection.
Appendix I Papers excluded from quantitative analysis.
Appendix J Methodology.
Appendix K Search strategy.
Appendix L Audit standards, data items and data collection methodology.